Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 22801674.
- Also identified by DOI 10.7326/0003-4819-157-2-201207170-00459.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for prostate cancer. The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer. The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation).This recommendation applies to men in the general U.S. population, regardless of age. This recommendation does not include the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer; the use of the PSA test for this indication is outside the scope of the USPSTF.
Medical subject headings
- Early Detection of Cancer
- Mass Screening
- Prostate-Specific Antigen
- Prostatic Neoplasms